A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFR

Efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring rare driver oncogene - Efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring rare driver oncogene

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049022

Enrollment

870

Registered

2022-09-26

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer harboring driver oncogene excepting EGFR

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with histologically or cytologically confirmed non-small cell lung cancer at clinical stage IIIA, IIIB, IIIC, IVA, IVB or postoperative recurrence that is not amenable to local treatment. (2) ALK, ROS1, MET, BRAF, KRAS, HER2, RET, NTRK are proven. (3) Patients who have received systemic chemotherapy between January 2015 and December 2021.

Exclusion criteria

Exclusion criteria: (1) Patients who are judged by the principal investigator or sub-investigator to be inappropriate for participation in this study. (2) Patients who had no driver mutation/translocation or EGFR mutation only.

Design outcomes

Primary

Measure	Time frame
Progression-free survival of immune checkpoint inhibitor therapy with or without chemotherapy	—

Secondary

Measure	Time frame
Response rate of immune checkpoint inhibitor therapy with or without chemotherapy, Immune-related adverse events, Response rate of molecular targeted therapy, Progression-free survival of molecular targeted therapy, Time to treatment failure of molecular targeted therapy, Overall survival from start date of the first line treatment, Cluster analysis of survival	—

Countries

Japan

Contacts

Public ContactAtsuto Mouri

Saitama Medical University International Medical Center Respiratory medicine

mouria@saitama-med.ac.jp09016016701

Outcome results